


- with breast cancer: a case-control study in Taiwan. *European Journal of Clinical Pharmacology* 2018;74:99–107.
26. Montastruc F, Khosrow-Khavar F, de Gernay S, et al. Tamoxifen and the risk of parkinsonism: a case/non-case study. *Eur J Clin Pharmacol* 2018;74:1181–1184.
 27. Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. *Ann Neurol* 2001;50:56–63.
 28. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain* 1991;114(Pt 5):2283–2301.
 29. Agalliu I, San Luciano M, Mirelman A, et al. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. *JAMA Neurol* 2015;72:58–65.
 30. Warøe BJ, Aasly JO. Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease. *Brain Behav* 2017;8:e00858-e.

Development of SARA^{home}, a New Video-Based Tool for the Assessment of Ataxia at Home

Marcus Grobe-Einsler, MD,^{1,2*}  Arian Taheri Amin,^{1,2} Jennifer Faber, MD,^{1,2} Tamara Schaprian, PhD,¹ Heike Jacobi, MD,^{1,3} Tanja Schmitz-Hübsch, MD,⁴ Alhassane Diallo, PhD,^{5,6} Sophie Tezenas du Montcel, PhD,⁷ and Thomas Klockgether, MD^{1,2}

¹German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ²Department of Neurology, University Hospital Bonn, Bonn, Germany ³Department of Neurology, University Hospital of Heidelberg, Heidelberg, Germany ⁴Experimental and Clinical Research Center, A Cooperation of Charité – Universitätsmedizin Berlin and Max-Delbrueck Center for Molecular Medicine, Berlin, Germany ⁵INSERM U1137-IAME, Department of Biostatistical Modeling, Clinical Investigation, Pharmacometrics in Infectious Diseases, University Paris Diderot, Paris, France ⁶Department of Epidemiology, Biostatistics and Clinical Research, APHP Bichat-Claude-Bernard Hospital, Paris, France ⁷Sorbonne Université, Institut, Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, University Hospital Pitié-Salpêtrière, Paris, France

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

*Correspondence to: Marcus Grobe-Einsler, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, Venusberg Campus 1, 53127 Bonn, Germany; E-mail: marcus.grobe-einsler@dzne.de

Relevant conflicts of interest/financial disclosures: There are no financial conflicts of interest to disclose.

Received: 9 October 2020; **Revised:** 20 November 2020; **Accepted:** 3 December 2020

Published online 12 January 2021 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28478

ABSTRACT: Background: Clinical scales such as the Scale for the Assessment and Rating of Ataxia (SARA) cannot be used to study ataxia at home or to assess daily fluctuations. The objective of the current study was to develop a video-based instrument, SARA^{home}, for measuring ataxia severity easily and independently at home.

Methods: Based on feasibility of self-application, we selected 5 SARA items (gait, stance, speech, nose-finger test, fast alternating hand movements) for SARA^{home} (range, 0–28). We compared SARA^{home} items with total SARA scores in 526 patients with spinocerebellar ataxia types 1, 2, 3, and 6 from the EUROSCA natural history study. To prospectively validate the SARA^{home}, we directly compared the self-applied SARA^{home} and the conventional SARA in 50 ataxia patients. To demonstrate feasibility of independent home recordings in a pilot study, 12 ataxia patients were instructed to obtain a video each morning and evening over a period of 14 days. All videos were rated offline by a trained rater.

Results: SARA^{home} extracted from the EUROSCA baseline data was highly correlated with conventional SARA ($r = 0.9854$, $P < 0.0001$). In the prospective validation study, the SARA^{home} was highly correlated with the conventional SARA ($r = 0.9254$, $P < 0.0001$). Five of 12 participants of the pilot study obtained a complete set of 28 evaluable videos. Seven participants obtained 13–27 videos. The intraindividual differences between the lowest and highest SARA^{home} scores ranged from 1 to 5.5.

Conclusion: The SARA^{home} and the conventional SARA are highly correlated. Application at home is feasible. There was a considerable degree of intra-individual variability of the SARA^{home} scores. © 2021 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Key Words: ataxia; digital assessment; SARA; home assessment

Ataxias refer to a group of degenerative diseases of the nervous system in which progressive ataxia is the core feature of clinical manifestation. They comprise diseases of both genetic and nongenetic origin. In most of them, there is prominent damage of the cerebellar cortex with consecutive cerebellar atrophy, but other parts of the nervous system, such as the spinal cord, basal ganglia, brain stem, and peripheral nerves, can be involved.

Proper assessment of the severity of ataxia is essential for clinical care, but even more for observational studies and interventional trials. This is done using clinical

scales, such as the Scale for the Assessment and Rating of Ataxia (SARA), an extensively validated scale that is applied by trained examiners in a clinical or research environment.¹ Such scales cannot be used to study the severity of ataxia at home or to assess day-to-day and within-day fluctuations, which are reported by almost all ataxia patients. It is therefore important to develop new instruments based on digital technology that allow measuring severity of ataxia at home.^{2,3} Digital technologies are providing new opportunities for this purpose. The urgent need for instruments that allow remote assessment of ataxia is underlined by the current COVID-19 pandemic that impeded patient care and led to interruption of observational and interventional trials in ataxia.

We here present a video-based assessment, SAR-A^{home}, that can be easily done independently of the presence of an examiner applied by ataxia patients themselves at home.

Patients and Methods

Description of SAR-A^{home}

Based on a detailed analysis of the feasibility of self-application at home, we selected 5 of the 8 SARA items (gait, stance, speech, nose-finger test, fast alternating hand movements) for SAR-A^{home}. The SAR-A^{home} sum score ranges from 0 to 28, with 0 indicating absence of ataxia and 28 being the most severe degree of ataxia. To facilitate implementation, we made small changes to the instructions including reduction of the walking distance to 5 m (1 way), performance of fast-alternating hand movements and nose-finger test on a chair allowing support of the feet for every patient and replacement of the investigator's finger that serves as the target in the nose-finger test by a tape-mark on the wall (Fig. 1). After instruction by an experienced rater, patients performed SAR-A^{home} without further assistance in front of a tablet camera. Severely affected patients were allowed support by a second person during gait and stance, in analogy to conventional SARA. If an item could not be performed, patients were asked to verbally share that information on video to be used for rating. SAR-A^{home} was performed in the hospital during the validation study and at home during the pilot study. The tablets were supplied by the study-site for the duration of the study and returned after the last recording for download and rating of videos.

Study Participants

To compare the results of the 5 SARA items selected for SAR-A^{home} with those of the complete SARA, we retrospectively analyzed the baseline data of 526 patients with spinocerebellar ataxia types 1, 2,

3, and 6 from the EUROSCA natural history study.^{4,5} To calculate progression and performance over time, we analyzed an additional 415 SARA scores from follow-up after 1 year, 416 after 2 years, and 336 after 3 years. To prospectively validate SAR-A^{home}, we directly compared the results of SAR-A^{home} with those of conventional complete SARA in 50 ataxia patients. To demonstrate feasibility of independent home recordings, we performed a pilot study in 12 patients. Inclusion criteria in both studies were clinical diagnosis of cerebellar ataxia and capability to comply with study protocol. Study participants of the prospective validation study and the pilot study were consecutively recruited from ongoing ataxia studies of the German Center for Neurodegenerative Diseases (DZNE), 4 patients from the prospective validation also participated in the pilot study. Patient characteristics are given in Table 1. All studies were approved by the responsible ethics committee. Written informed consent was obtained from all study participants at enrollment.

Prospective Validation Study

The prospective validation study was performed in the DZNE clinical trial unit in Bonn, Germany. The SARA score was obtained from all study participants by a trained and experienced examiner. Subsequently, study participants received oral instructions on how to perform SAR-A^{home}. Subjects then performed SAR-A^{home} independently without any further assistance using a tablet device. Only subjects at risk of falling received support, if necessary. Videos were rated by a trained and experienced rater (T.K.) who had no knowledge of the conventional SARA score.

Pilot Study

To demonstrate feasibility under real-life conditions at home and collect first data about daily fluctuation and training effects, 12 ataxia patients performed SAR-A^{home} twice daily (morning and evening) for a period of 14 days in a pilot study. Initial instructions were given by a trained investigator either during a study visit (n = 7) or via a video call (n = 5). Therefore, baseline SARA was not always available in the pilot study. In addition, subjects received detailed instructions for each item via a printout or digitally presented on the tablet device supplied by the DZNE that was also used to record SAR-A^{home} performance on video (Fig. S1). All videos of the pilot study were rated by an experienced rater (M.G.E.).

Statistical Analysis

A linear model was used to compare SARA and SAR-A^{home} items in the retrospective and prospective analysis, and Pearson's correlation was calculated. To see if the differences in the scores of single items were similar




FIG. 1. SARA^{home} setup. (A) Gait is performed on a 5-m walkway in front of the tablet or smartphone placed on a tripod. Marks on the floor indicate position of the tripod (0 m), 2- and 5-m distances. Patient walks back and forth, as indicated by the dashed line (1). Subsequently, the patient walks from the 5-m mark toward the camera in tandem (2). (B) Stance is performed on the 2-m mark at a 45° angle to the camera. If practicable, 3-foot positions are taken (1-3). (C) Fast alternating hand movements and speech are performed sitting on a chair at the 2-m position in front of the camera. (D) Nose-finger test is performed sitting on a chair at the 2-m position that is rotated by 90° so that the patient faces the wall. Pointing movements are performed toward a mark attached to the wall at eye height.

across the spectrum of severity, we performed a Bland–Altman analysis of the respective 5 items of SARA with SARA^{home} scores from the prospective validation study. To calculate progression and performance over time between SARA and SARA^{home} (retrospective data), a bivariate linear mixed model was used. In the pilot study, a 2-way repeated-measures analysis of variance was performed to evaluate the effect of different times (morning/evening) and day of assessment on SARA^{home} score. To determine how many recording days are required to obtain a representative estimate of the entire 14-day period, we calculated mean values and

confidence intervals for cumulative days. All analyses were done using GraphPad Prism version 7.02 and R versions 3.4.3. and 3.5.1.

Results

The SARA^{home} score extracted from the EUROSCA baseline data was highly correlated with the SARA score ($r = 0.985$, $P < 0.0001$; Fig. S2a). Progression of SARA^{home} and SARA were also highly correlated ($r = 0.935$, $P < 0.0001$).

TABLE 1. Characteristics of patients of the validation and pilot studies

	Validation study (n = 50)	Pilot study (n = 12)
SCA1 (n)	2	4
SCA2 (n)	2	0
SCA3 (n)	12	3
SCA6 (n)	6	0
MSA-C (n)	7	2
Recessive ataxia (n)	11	0
Friedreich (n)	2	1
Others (n)	8	2
Age (years), mean \pm SD (range)	51.4 \pm 13.1 (26–80)	41.1 \pm 12.8 (24–58)
Disease duration (years), mean \pm SD (range)	10.2 \pm 7.3 (0–33)	4.4 \pm 2.9 (0–10)
SARA, mean \pm SD (range)	14.2 \pm 7.2 (0–32)	Not available ^a
SARA ^{home} , mean \pm SD (range)	9.3 \pm 6.0 (0–25)	7.5 \pm 5.0 (0.1–17.8) ^b

Age, disease duration, and SARA score are shown as mean \pm standard deviation (range).

^aBaseline SARA was not available for all participants because 5 of the 12 patients in the pilot study had no study visit in the hospital and received only online instructions.

^bMean SARA^{home} from all available recordings.

In the prospective validation study, no falls or injuries occurred during testing. The SARA^{home} score derived from video rating was highly correlated with the conventional complete SARA score ($r = 0.9254$, $P < 0.0001$; Fig. S2b). Item-specific analysis showed correlation coefficients ranging from 0.7594 for fast alternating hand movements to 0.9433 with $P < 0.0001$ for gait (Table S1). Bias of Bland–Altman analysis was 0.76, and >95% of all data points lay within the 95% limits of agreement, suggesting that SARA and SARA^{home} are similar across the entire spectrum of severity (Fig. S3).

Five of 12 participants obtained a complete set of 28 recordings, and 7 participants obtained at least 1 recording per day. A comprehensive list of available recordings is given in Table S2. In total, 7 of 293 recordings were rated as missing because of incorrect performance of single items (stance, 2; alternating hand movements, 5). There were no falls or injuries during the home recordings. The intraindividual differences between the lowest and highest SARA^{home} score ranged from 1 to 5.5 (mean \pm SD, 3.3 ± 1.3 ; see Fig. S4). The time of assessment (morning vs evening) had no statistically significant effect on SARA^{home} score ($F_{1,4} = 1.435$, $P = 0.297$), and there was no significant training effect during the 14 days of assessments ($F_{13,52} = 1.234$, $P = 0.238$). Interaction between these terms was also not statistically significant ($F_{13,52} = 0.881$, $P = 0.577$; Table S3). The width of

confidence intervals of SARA^{home} scores dropped from 4.77 for 1-day to 1.25 for 14-day recordings. For all recording periods longer than 3 days, confidence intervals were less than twice the 14-day value (Fig. S5).

Discussion

We have developed and validated a video-based assessment of ataxia, SARA^{home}, that is derived from the original SARA and can be self-applied by patients at home. A retrospective analysis of data from the EUROSCA natural history study and a prospective validation study performed in 50 ataxia patients showed high correlations between SARA^{home} and conventional SARA and similarity of both scales across the spectrum of severity. We further demonstrated the feasibility of home recordings in a pilot study in 12 ataxia patients.

There have been several attempts to develop digital ataxia assessment tools, which are applicable to home testing.^{6–10} Some of these approaches focused on single SARA items,^{6–8} whereas others introduced items that are not included in SARA.^{8–10} One example is a tool that uses commercially available devices from video games (Microsoft Kinect, Leap Motion Controller) together with a computer screen to record performance of pediatric ataxia patients in 6 of 8 SARA items.¹⁰ Other instruments relied on accelerometers.^{6,8} Real data from home recordings with any of these tools have not been published.

SARA^{home} has the principal advantage that it is completely video-based without the need for specific hardware or an examiner. SARA^{home} can be performed with any tablet or smartphone that possesses a camera. In collaboration with a commercial partner, we have developed an app that patients can download on their own devices. The app provides detailed instructions for users and enables recording as well as secure transfer of SARA^{home} video recordings for off-line rating. As SARA^{home} is directly derived from SARA, and SARA^{home} and SARA scores are highly correlated, SARA^{home} may partly substitute for a conventional SARA assessment in hospitals or research institutions, for example, between scheduled study visits or in situations, such as the COVID-19 pandemic, in which hospital visits are not possible. Currently, SARA^{home} is still dependent on off-line rating by a trained rater, which eliminates inter-rater variability. Intrarater reliability has not been explored in this study, but we expect similar results as those for SARA. In the future, subjective rating may be replaced by automatic video tracking.

Our pilot study in a small group of ataxia patients demonstrated that SARA^{home} can be safely and reliably performed by patients independently at home.

However, a possible limitation is the applicability in very severely affected patients and patients with major cognitive impairment who may need supervision. For the first time, this study provided data on fluctuation of ataxia severity. Fluctuations of the SARA^{home} score of at least 1 point were observed in all patients. However, we detected neither systematic differences of ataxia severity between morning and evening nor a training effect. To fully determine the causes of fluctuations, larger trials are required. Based on the analysis of confidence intervals for cumulative days, we suggest that a recording period of 4 days is representative for the entire 14-day period and provides a more meaningful measure of ataxia severity than a single conventional SARA assessment in the hospital. ■

Acknowledgments: This study was funded by the I2A innovation fund of the DZNE. T.K. is member of the European Reference Network for Rare Neurological Diseases (ERN-RD, project number 739510). We thank the members of the EUROSCA study group for obtaining the data of the EUROSCA study.

References

- Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. *Neurology* 2006;66(11):1717–1720.
- Bloem BR, Henderson EJ, Dorsey ER, et al. Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care. *Lancet Neurol* 2020;19(7):623–634.
- Warmerdam E, Hausdorff JM, Atrsaei A, et al. Long-term unsupervised mobility assessment in movement disorders. *Lancet Neurol* 2020;19(5):462–470.
- Jacobi H, du Montcel ST, Bauer P, et al. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. *Lancet Neurol* 2015;14(11):1101–1108.
- Schmitz-Hubsch T, Coudert M, Bauer P, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. *Neurology* 2008;71(13):982–989.
- Arcuria G, Marcotulli C, Amuso R, et al. Developing a smartphone application, triaxial accelerometer-based, to quantify static and dynamic balance deficits in patients with cerebellar ataxias. *J Neurol* 2019;267:625–639.
- Jaroensri R, Zhao A, Balakrishnan G, et al. A video-based method for objectively rating ataxia. *PMLR* 2017;68:204–216.
- Matsushima A, Yoshida K, Genno H, et al. Clinical assessment of standing and gait in ataxic patients using a triaxial accelerometer. *Cerebellum Ataxias* 2015;2:9.
- Gajos KZ, Reinecke K, Donovan M, et al. Computer mouse use captures ataxia and parkinsonism, enabling accurate measurement and detection. *Mov Disord* 2020;35(2):354–358.
- Summa S, Schirinzi T, Bernava GM, et al. Development of SARAHome: a novel, well-accepted, technology-based assessment tool for patients with ataxia. *Comput Methods Programs Biomed* 2019;188:105257.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.

Impaired Inhibitory Control of Saccadic Eye Movements in Cervical Dystonia: An Eye-Tracking Study

Federico Carbone, MD,¹ Philipp Ellmerer, MD,¹ Marcel Ritter, MSc,² Sabine Spielberger, MD,¹ Philipp Mahlke, MD, PhD,¹ Eva Hametner, MD,¹ Anna Hussl, MD,¹ Anna Hotter, MD,¹ Roberta Granata, MD,¹ Klaus Seppi, MD,¹ Sylvia Boesch, MD,¹ Werner Poewe, MD,¹ and Atbin Djamshidian, MD, PhD^{1*}

¹Department of Neurology, Medical University Innsbruck, Innsbruck, Austria ²Interactive Graphics and Simulation Group, University of Innsbruck, Innsbruck, Austria

ABSTRACT: Background: The pathophysiology of cervical dystonia is still unclear. Recent evidence points toward a network disorder affecting several brain areas. The objective of this study was to assess the saccadic inhibition as a marker of corticostriatal function in cervical dystonia.

Methods: We recruited 31 cervical dystonia patients and 17 matched healthy controls. Subjects performed an overlap prosaccade, an antisaccade, and a countermanding task on an eye tracker to assess automatic visual response and response inhibition.

Results: Cervical dystonia patients made more pre-mature saccades ($P = 0.041$) in the overlap prosaccade task and more directional errors in the antisaccade task ($P = 0.011$) and had a higher rate of failed inhibition in the countermanding task ($P = 0.001$).

Conclusions: The results suggest altered saccadic inhibition in cervical dystonia, possibly as a consequence of dysfunctional corticostriatal networks. Further studies are warranted to confirm whether these abnormalities are affected by the available therapies

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

*Correspondence to: Dr. Atbin Djamshidian, Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria; E-mail: atbin.djamshidian-tehrani@i-med.ac.at

Relevant conflicts of interest/financial disclosures: Nothing to report.

Funding agencies: The authors received no specific funding for this work.

Received: 24 September 2020; **Revised:** 24 November 2020; **Accepted:** 16 December 2020

Published online 8 January 2021 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28486